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ArrhythmiasBackground: Clinical independent predictors of inducible sustained ventricular tachycardia (VT) during electro-
physiologic study (EPS) are not known in patients with chronic Chagas' heart disease. The purpose of this inves-
tigation was to ﬁll this gap.
Methods: The medical charts of 47 patients with a positive serology for Chagas' disease who had undergone EPS
between September 2006 and July 2012 at our institution were reviewed. Reasons for the EPSwere the presence
of unexplained syncope, non-sustained ventricular tachycardia (NSVT) on either resting ECG or 24 h-Holter
monitoring as well as a LVEF b 55% and N35% at echocardiography. A stepwise logistic regression analysis was
performed to identify noninvasive predictors of inducible sustained VT/ventricular ﬁbrillation during EPS.
Results: On univariate analysis, syncopal episodes (p = 0.04), amiodarone therapy (p b 0.005), diastolic blood
pressure (p = 0.03), creatinine serum levels (p b 0.001), potassium serum levels (p b 0.001), and lengthening
of the QRS complex (p = 0.03) were associated with inducible sustained VT during EPS. In the multivariate
model, amiodarone therapy (p = 0.03; hazard ratio = 10; Wald coefﬁcient = 4.5; 95% conﬁdence interval 1.2
to 85.2) was the only variable retained as independent predictor of inducible sustained VT during EPS.
Conclusion: Amiodarone therapy was the only independent variable associated with sustained VT inducibility
during EPS in patients with chronic Chagas' heart disease.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chagas' disease affects about 10 million people in Latin America, an-
other 25 million are at risk of acquiring the disease, and about 10,000
people die of the disease annually. Chagas' disease has become global
as a result of international immigration, about 750,000 people with
chronic Chagas' disease are living outside South America, mainly in
the United States and Europe [1]. As a result, the world economic bur-
den of Chagas' disease is US$ 7.9 billion annually, higher than that
seen in cervical or oral cancer, and affects the economy of both endemic
and non-endemic countries [2].
The disease is caused by the protozoan Trypanosoma cruzi, it is trans-
mitted to humans by eyemucosa or skin lesion contact with the feces of
sucking-bugs. However, other sources of transmission, like oral trans-
mission, have become important nowadays. Initial infection occurs in
early infancy, but the clinicalmanifestations of Chagas' cardiomyopathy,34, 14096-430 Ribeirão Preto,
land Ltd. This is an open access articlwhich affects about 30% of infected patients, appear up to 20 years later
[3]. Chagas' cardiomyopathy manifests by chronic systolic heart failure
(CHF) [4], thromboembolism [3], malignant ventricular arrhythmias
[5,6], and sudden cardiac death (SCD) [7].
SCD affects about 5% of the general, unselected population with
chronic Chagas' disease [7]. It is the mode of death in 17 to 50% of pa-
tients with this condition [8,9], and afﬂicts patients with overt chronic
Chagas' heart disease [10], particularly those with ventricular dysrhyth-
mias on the 12-lead ECG and mild to moderate left ventricular systolic
dysfunction [11]. In the vast majority of cases, SCD is caused by
sustained ventricular tachycardia (VT) degenerating into ventricular
ﬁbrillation (VF) or VF itself [7].
An electrophysiologic study (EPS) is useful for identifying chronic
Chagas' disease patients at high risk of SCD. In fact, patientswith chronic
Chagas' heart disease in whom sustained VT/VF are induced during EPS
have a higher risk of SCD in comparison to those in whom such malig-
nant arrhythmias are not induced [12]. EPS is not widely available and
impractical to be offered to millions of people. Nonetheless, it would
be of interest to predict on clinical grounds which patients will develop
sustained VT/VF during EPS. This might be used as means of selecting
patients for EPS. Accordingly, the present study was undertaken ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical and laboratory characteristics of a cohort of patients with chronic Chagas' heart
disease with inducible or no inducible sustained ventricular tachycardia during electro-
physiologic study.
Variables SVT (n = 12) No SVT (n = 35)
Age (years) 57 ± 9 57 ± 12
Male 8 (67%) 21 (60%)
NYHA III/IV 1 (8%) 6 (17%)
Syncope 9 (75%) 13 (37%)⁎
ACEI/ARB 10 (83%) 29 (83%)
Beta-blockers 7 (58%) 29 (83%)
Digoxin 3 (25%) 9 (26%)
Diuretic 6 (50%) 18 (51%)
Spironolactone 6 (50%) 11 (31%)
Amiodarone 8 (67%) 6 (17%)⁎⁎
Heart rate 66 ± 11 69 ± 13
SBP (mmHg) 113.6 ± 13.6 127.3 ± 24.9
DBP (mmHg) 70.9 ± 8.3 80.3 ± 13.1⁎⁎⁎
Sodium (mEq/L) 138.9 ± 5 140.4 ± 2.9
Potassium (mEq/L) 4.1 ± 0.2 4.3 ± 0.4
Creatinine (mg/dL) 1.1 ± 0.3 1.3 ± 0.5⁎⁎
Hemoglobin (g/dL) 13.6 ± 0.8 13.6 ± 1.7
SVT = sustained ventricular tachycardia; ACE/ARB = angiotensin converting enzyme
inhibitor/angiotensin receptor block; SBP = systolic blood pressure; DBP = diastolic
blood pressure.
⁎ p = 0.04.
⁎⁎ p b 0.005.
⁎⁎⁎ p = 0.03.
Table 2
Electrocardiographic ﬁndings and echocardiographic features in patients with chronic
Chagas' heart disease with inducible or no inducible malignant arrhythmias during elec-
trophysiologic study.
Variables SVT (n = 12) No SVT (n = 35)
Atrial ﬁbrillation 1 (8%) 7 (20%)
Pacemaker 3 (25%) 6 (17%)
Left bundle branch block 0 (0%) 5 (14%)
LAFB 3 (25%) 13 (37%)
RBBB 3 (25%) 16 (46%)
Low QRS voltage 0 (0%) 1 (3%)
VPC 4 (33%) 4 (11%)
NSVT 10 (83%) 21 (60%)
QRS duration (ms) 142 ± 37.1 137.9 ± 28⁎⁎⁎
LVDD (mm) 60.1 ± 9.2 58.1 ± 9
LVSD (mm) 46.2 ± 10.3 43.4 ± 12.4
Right ventricle (mm) 21.1 ± 5.2 23.8 ± 6.7
SWMA 2 (17%) 4 (11%)
LVEF (%) 45.8 ± 13.2 53.1 ± 15.7
SVT = sustained ventricular tachycardia; LFAB = left anterior fascicular block; RBBB =
right bundle branch block; VPC = ventricular premature contractions; NSVT = non-
sustained ventricular tachycardia; LVDD = left ventricular diastolic diameter; LVSD =
left ventricular systolic diameter; SWMA = systolic wall motion abnormalities; LVEF =
left ventricular ejection fraction.
⁎⁎⁎ p = 0.03.




The medical charts of patients with a positive serology for Chagas'
disease who had undergone EPS between September 2006 and July
2012 at our institution were considered for the study. Inclusion criteria
were an EPS performed for the following reasons: unexplained syncope,
non-sustained ventricular tachycardia (NSVT) on either resting ECG or
24 h-Holter monitoring as well as a LVEF b 55% and N35% at echocardi-
ography. The diagnostic work-up, besides the EPS, consisted of history-
taken and physical examination at presentation, 12-lead ECG, standard
laboratory tests, and 2-D echocardiography. The New York Heart
Association Functional Class, heart rate, systolic and diastolic blood
pressure were noted on study admission.
All patients with left ventricular systolic dysfunction were treated
with beta-blockers and angiotensin converting enzyme inhibitors/
angiotensin receptor block (ACEI/ARB) at target or maximal tolerated
doses. Those with systemic and pulmonary congestion received
diuretics and/or digitalis when appropriated. Patients were given amio-
darone at the discretion of the referral doctor. Overall, 39 (83%) patients
were on ACEI/ARB, 36 (76%) on beta-blockers at target or maximal tol-
erated daily dose, and 24 (51%) on diuretics. Seventeen (35%) patients
received treatment with spironolactone, and 14 (29%)were on amioda-
rone. Mean daily dose of enalapril was 18.7± 10.2mg, mean daily dose
of captopril 70.7±19.8mg,mean daily dose of losartan 45.4±10.1mg,
mean daily dose of carvedilol 26 ± 18 mg, mean daily dose of atenolol
37.2 ± 17.7 mg, mean daily dose of digoxin 0.12 ± 0 mg, and mean
daily dose of amiodarone 278.6 ± 112.2 mg. Such medications were
maintained at the time of EPS.
During the EPS, ventricular stimulation was performed only in the
right ventricular apex, using 3 extra-stimuli with up 200 ms interval
at most. The cycle length of extra stimuli were 600, 500 and 430 ms,
respectively.
2.2. Statistical analysis
Continuous variables are shown as mean ± standard deviation,
whereas categorical variables are presented as percentages. Continuous
variables between inducible and non-inducible SVT groups were com-
pared using the unpaired T Test, while categorical variables between
both groups were compared by the χ-square test. Differences between
variables at the level of p b 0.05were entered in stepwise logistic regres-
sion analysis to identify noninvasive predictors of inducible sustained
VT/VF during EPS.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology: Shewan LG and Coats AJ. Ethics in the authorship and
publishing of scientiﬁc articles. Int J Cardiol 2010;144:1–2.
3. Results
A total of 47 patients fulﬁlled the inclusion criteria andwere entered
in the study. During EPS, sustained VTwas induced in 12 (25%) of 47 pa-
tients. By contrast, VF was induced in none of the patients. Table 1 lists
the clinical characteristics of patients with inducible and non-inducible
sustained VT during EPS. Table 2 depicts electrocardiographic and echo-
cardiographic variables in both patients' groups. Also, the AH interval
was 94.4 ± 25.8 ms in patients with and 98 ± 48.7 ms in patients
with no inducible sustained VT (p N 0.05), while the HV interval was
55.4 ± 13.5 ms in patients with sustained VT and 57.6 ± 26.3 ms
(p N 0.05) in patients with no inducible sustained VT. The cycle length
of inducible sustained VT was 309 ± 49 ms. The episodes of sustainedVT were treated with cardioversion in 4 (33%) out of 12 patients, and
a burst of ventricular stimulation in 7 (58%) out of 12 patients. One
episode of inducible sustained VT terminated spontaneously.
On univariate analysis, history of syncopal episodes (p= 0.04), ami-
odarone therapy (p b 0.005), diastolic blood pressure (p= 0.03), creat-
inine serum levels (p b 0.001), potassium serum levels (p b 0.001), and
lengthening of the QRS complex during EPS (p= 0.03) were associated
with inducible sustained VT during EPS. In the multivariate model,
however, amiodarone therapy (p = 0.03; hazard ratio = 10; Wald
coefﬁcient = 4.5; 95% conﬁdence interval 1.2 to 85.2) was the only
variable retained as an independent predictor of inducible sustained
VT during EPS.
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This study clearly shows that one quarter of patients with chronic
Chagas' heart disease with mild left ventricular systolic dysfunction
and/or syncope/NSVT has inducible sustained VT during EPS, and that
the vastmajority of themneed electric intervention to terminate the ar-
rhythmia. Furthermore, only amiodarone therapy in this settingwas in-
dependently associated with an inducible sustained VT during EPS in
the multivariable model.
The prevalence of sustained VT induced during EPS observed in this
cross-sectional investigation is somewhat lower than that found by
Silva et al. [12]. In fact, Silva et al. were able to induce sustained VT
and VF during EPS in 25 (32%) and 4 (5%), respectively, of 78 patients
with chronic Chagas' heart disease with mild left ventricular systolic
dysfunction and NSVT. Twenty-two (78%) of the patients died, 16 of
them suddenly, in a 56 ± 38 months follow-up [12]. It is conceivable
that the high frequencywithwhich beta-blockerswere used in or inves-
tigation in comparison with the study by Silva et al. [12] can account, at
least in part, for the difference among studies. In fact, in the Silva et al.
study [12], beta-blockers were not used. On the other hand, beta-
blocker therapy has been found to have a beneﬁcial effect experimental-
ly and in patients with chronic Chagas' heart disease [13–16], similarly
to what happens in an experimentalmodel of catecholamine cardiomy-
opathy [17]. In patientswith chronic Chagas' heart disease, beta-blocker
therapy parallels the beneﬁcial effect observed in non-Chagas' disease
patients regarding the appearance ofmalignant ventricular arrhythmias
[18]. Collectively, these ﬁndings suggest that beta-blocker therapy can
be useful for reducing inducibility of sustained VT during EPS in patients
with mild to moderate left ventricular systolic dysfunction and NSVT
during EPS.
The prevalence of inducible sustained VT during EPS is consistent
with the high frequency of syncopal episodes experienced by Chagas'
disease patients with left ventricular systolic impairment in our study,
and probably reﬂects the underlyingmechanismbehindmalignant ven-
tricular arrhythmias in patients with this condition. In patients with
chronic Chagas' heart disease, there are areas of normal myocardium
intermingledwith areas of reparative ﬁbrosis.Moreover, amononuclear
cell inﬁltration coexists with such areas of ﬁbrosis. This can lead to areas
of slow conduction electric stimulus close to scar areas, thus triggering
many foci of re-entry throughout themyocardium,mainly in the epicar-
dial layer [6,19]. Furthermore, parasympathetic denervation [20,21] can
lead to intracardiac autonomic imbalance, thus aggravating the arrhyth-
mic threshold and provokingmalignant arrhythmia appearance even in
patients with mild left ventricular systolic dysfunction. Collectively,
such ﬁndings can explain, at least in part, the prevalence of 25% of
sustained VT induced at EPS in Chagas' disease patients without severe
left ventricular systolic dysfunction.
Our study also contrasts with Silva et al. [12] regarding the associa-
tion of male patients and age with higher probability of induction of
sustained VT during EPS in the logistic regression analysis. In fact, in
our study, such variables were not associated with sustained VT during
EPS either on univariate or multivariate analysis. However, it must be
considered that the mean age in Silva et al. study was lower than ob-
served in ours, this might explain the difference found in both study
populations [12]. Another difference between our study and Silva et al.
is that we did not observe an increase in the proportion of sustained
VT inducibility in male patients sex. Since beingmale is an independent
predictor of left ventricular remodeling [22], and the prevalence ofmale
patients was similar to that found in the Silva et al. study [12], it would
be reasonable to expect its association with sustained VT inducibility.
Nonetheless, we have no explanation for the difference observed in
our study as compared with that of Silva et al. [12].
The results of this investigation are in contrast to other studies in
which several clinical and laboratorial variables were associated with
SCD, a condition which can be predicted by sustained VT inducibility
during EPS [11]. Such clinical characteristics are represented byelectrocardiographic changes (left anterior fascicular block, QT disper-
sion, and premature ventricular contractions) [23] as well echocardio-
graphic abnormalities (left ventricular diastolic diameter N 70 mm and
apical aneurysm) [9], which have independently been associated with
SCD in patients with Chagas' cardiomyopathy. However, our sample
size was smaller than that enrolled such studies. Also, the severity of
left ventricular systolic impairment observed in our investigation was
lesser than these other studies. Therefore, such differences can explain
the discrepancies between our study and those reported previously.
The striking feature of this investigation was the independent asso-
ciation between amiodarone therapy and inducible sustained VT during
EPS. Amiodarone has long been used in the treatment of ventricular ar-
rhythmias, particularly sustained VT, in patients with chronic Chagas'
heart disease [24]. As expected, however, there is no evidence-based
medicine to support theuse of amiodaronebecause no randomized, pla-
cebo controlled trial have been performed because this disease is largely
neglected. Amiodarone use has been associated with several types of
complications in Chagas' disease patients probably due to the chronical-
ly high dose. The complications include thyroid disease (hypo or hyper-
thyroidism) in 21% to 39% of cases [25,26], restrictive pulmonary disease
[27], ocular disease and gray-skin discoloration. A pro-arrhythmic effect
secondary to chronic amiodaroneuse is supposed to have been occurred
in one patient with chronic Chagas' heart disease [28].
Apart from the side-effects associated with amiodarone use, amio-
darone therapy has been found to increasemortality in non-Chagas' dis-
ease patients with CHF. In fact, a multivariable study of patients in
COMET trial has shown that amiodarone therapy increased the risk of
death independently of the New York Heart Association classiﬁcation,
including milder forms (Class II) of the CHF syndrome, which was driv-
en by circulatory death, as the drug did not interferewith the risk of SCD
[29]. A similar ﬁnding has been observed in the SCD-HF trial in non-
Chagas' disease patients with more advanced forms (Class III) of the
syndrome. Itmust be emphasized, however, that in such studies neither
syncopal episodes nor NSVT were inclusion criteria [30].
In a population comprised of patients with Chagas' and non-Chagas'
cardiomyopathy, amiodarone therapy has been associated with all-
cause mortality driven by death from progressive heart failure, but no
effect has been observed on sudden cardiac death [31]. It should be
noted, nonetheless, that NSVT is very frequently found in patients
with chronic Chagas' heart disease, this may suggest a different effect
of amiodarone in Chagas' disease heart failure.
One possibility of the independent association between amiodarone
use and sustained VT inducibility during EPS is that amiodarone is a
marker, not a cause, of patients more prone to develop malignant
arrhythmia. For this reason, some authors do not recommend using
treatment modality in multivariable models [32]. Another possibility is
that amiodarone may have facilitated the appearance of sustained VT
because its effects on myocardium with multiple areas of scarring, as
observed in patients with chronic Chagas' heart disease [19]. Under
such circumstances, amiodarone can produce different degrees of
dromotropism in different areas of ventricular myocardial tissue, thus
allowingmultiple areas of reentrant circuits to occur, culminating in in-
ducible sustained VT [28]. Finally, it is conceivable that amiodarone can
slow stimulus conduction in pre-existent circuits, in line with the cycle
length of the sustained VT induced at EPS in our study, thus becoming
the ventricular arrhythmia more sustainable.
In conclusion, amiodarone therapy is independently associated
with sustained VT inducibility at EPS in patients with chronic Chagas'
disease. Further studies are necessary to establish other clinical
predictors of malignant ventricular arrhythmias induced by EPS, and
conﬁrm (or discard) a causal relationship between amiodarone use
and sustained VT induced by EPS, as observed in our study.
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